While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design
| INTRODUCTION: INSIGHTS INTO IMMUNE TOLERANCE IN ALLE RGY AN D CANCER
The immune system strives to strike a fine balance to maintain homoeostasis. Therefore, after elimination of pathogens an immune regulation phase follows, facilitated by checkpoint molecules, CD4+ CD25+ FoxP3+ natural regulatory T cells (Tregs), 1 and downregulate IgE-mediated signalling 10 ; or (iii) promote differentiation of tolerogenic M2b macrophages. 11 While investigation into immune tolerance in allergy provided some insights, it is unclear which of these mechanisms may drive tolerance or which specific biomarkers could be used to predict clinical response to AIT. Two checkpoint molecules, the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1), play key roles in restricting T-cell activation and inducing immunological tolerance that contribute to immunosuppressive environments in cancer by multiple mechanisms. They restrict recruitment, activation and proliferation of cytotoxic CD8+ T cells, 13 and their effects are amplified by tumour cells expressing CTLA-4 14 or PD-1 ligand (PD-1L). 15 These findings opened new avenues for intervention by so-called checkpoint inhibitors.
The anti-CTLA-4 monoclonal ipilimumab was the first clinically applied antibody that conferred tangible improvements in the treatment of metastatic melanoma, 16 with long-term survivors after 3 and 5 years. 17 The anti-PD-1 inhibitor antibodies, nivolumab and pem- levels of cytokines, such as TGFb. 41 Specifically, the smoke compound acrolein promotes regulatory cells via the arylhydrocarbon receptor (AhR), thereby increasing malignant growth, while decreasing the risk for allergic sensitization. 42 High numbers of infiltrating Tregs are associated with poor prognosis in many cancers, including ovarian, pancreatic, lung cancer, glioblastoma or melanoma. 41 Therefore, cancer immunotherapy targeting Tregs while breaking tumour tolerance can also break tolerance to self, 43 highlighting the fine balance between antitumour immune activation and the risk of autoimmunity.
| B cells and Bregs
B cells play key roles in inflammation, antigen presentation and antibody production in the context of allergy. Their contributions in cancer are less well delineated.
Tumour-infiltrating B cells (TiBCs) have been detected in human solid malignancies, including melanoma, 44, 45 breast, ovarian, cervical, colorectal and non-small-cell lung cancer. As in allergy, 46 TiBCs show evidence of antigen-driven expansion and somatic hypermutation, implying active in situ antibody affinity maturation in the cancer tissue. 45 The presence of TiBCs, and B cells in tertiary lymphoid 
| Eosinophils
Eosinophils were found mainly antitumorigenic in solid tumours such as bladder, gastrointestinal, melanoma, prostate, with only some studies showing a detrimental effect in favour of tumour growth such as in the case of Hodgkin lymphoma. 62 Mechanistically, CCL1
produced by tumour cells can attract eosinophils (via CCR3) that may interfere with tumour growth. 63 Tumour cells can stimulate eosinophils to produce IL-18, which in turn facilitates eosinophil-cancer cell interactions leading to tumour cell death. 64 Production and secretion of ROS and cytotoxic mediators, typical eosinophil mediators, were found antitumorigenic in many cancer studies. 65 Nevertheless, the growth factor APRIL could support growth of malignant plasma cells in bone marrow in a multiple myeloma mouse model. 66 More recent studies place eosinophils as first line "sensors" for the general antitumour immune response, showing for example, that intratumoral eosinophils are crucial for the recruitment of antitumour CTLs in melanoma. 67 On the other hand, lung eosinophils were shown to induce Treg infiltration and consequently support lung metastasis. 68 Lastly, eosinophils are involved in curative processes induced by checkpoint inhibitor immunotherapies (eg, ipilimumab or pembrolizumab 69 ).
Hence, numerous findings suggest that eosinophils can be an immunotherapeutic effector cell either being activated by immunotherapies such as checkpoint inhibitors, or granulocytemacrophage-colony-stimulating factor (GM-CSF)-based vaccines, 70 or perhaps by adoptive transfer of these cells in an appropriate setting. 71 
| Epithelial cells
The essential contribution of the epithelial barrier to a balanced immune response is well established. For oral antigens, the site of antigen uptake and its particulate nature is decisive for the subsequent immune response. 72 Antigen passage through mucus-producing goblet cells has been specifically associated with tolerance induction. 73 In allergy as well as cancer, the cell surface receptor repertoire of epithelial cells includes the high- 74 and the low-affinity IgE Fc receptors facilitating antigen passage and directing antigen presentation. 75 The epithelium is additionally an important cytokine source, profoundly modulating the immune response (Table S1 ).
In the intestinal tract, extracellular vesicles physiologically produced from intestinal epithelial cells contribute to innate immunosuppression, 76 which may contribute to oral tolerance-or cancer progression.
| MOLECULES IN IMMUNE TOLERANCE: FROM ALLERGY TO CANCER (SEE OVER VIEW IN TABLE 2)

| IgG4 antibodies
IgG4 is the least abundant subclass of IgG in normal human serum, but it may reach elevated levels following chronic exposure to antigen, or during inflammation. IgG4 has unique structural characteristics that are responsible for its inability to fix complement, low affinity for activating FccRs, and relatively high affinity for the inhibitory Fc receptor FccRIIb. 26 IgG4 has a unique ability to undergo Fab-arm exchange, resulting in the formation of bispecific antibodies which are functionally monovalent, and are therefore not able to cross-link antigens to form large immune complexes. 44 For these rea- 
| IgE and IgG repertoires in allergy and cancer
New-generation sequencing for immunoglobulin repertoire analysis 78 was applied in subcutaneous AIT 79 and longitudinal studies of cancer progression. 80 Also the IgG repertoire of healthy individuals contained antibodies to tumour-associated carbohydrate antigens, with a possible function immunosurveillance. cell activation 86 and also reduce neutrophil apoptosis and stimulate their release of pro-tumorigenic IL-8. The expression of FLC was found to be a biomarker for poor prognosis in basal-like breast cancer. 87 In a preclinical melanoma model, it was further demonstrated that FLC-induced mast cell activation-stimulated tumorigenesis. 87 As FLC were found in the stromal tissues of a great number of human tumours, one could speculate that overall FLC may contribute to cancer growth and progression. 101 All these suggest an important role of mast cell mediators in immunoregulation.
| Free light chains (FLC)
| Regulatory cytokines and chemokines
| Lipocalins
Many innate defence proteins are differentially regulated in allergy and cancer, for instance lipocalin-2 (LCN2; NGAL). LCN2 is highly expressed in the liver, bone marrow, spleen, salivary gland, the colon, the lung and the kidney. LCN2 is upregulated in various cancer types and has been proposed as a cancer biomarker. [102] [103] [104] LCN2 binds iron through iron-chelating compounds. 105 As such, it is involved in numerous processes including innate immunity, apoptosis and renal development. It can also form complexes with the matrix-metallopeptidase 9 (MMP9, a 92-kDa gelatinase), itself being a poor prognostic factor in several cancer types. 106 Increased iron raises the cancer risk and as a participant in iron homoeostasis also LCN2 is upregulated in various cancers. 107 Contrastingly, decreased LCN2 and serum iron are associated with allergy. 108 Some exogenous antigens have a striking structural resemblance with human LCN2, 109, 110 suggesting potential interference with the iron loading of endogenous LCN2 and affecting its immunomodulatory potency. Taken together, LCN2
could assume divergent immune roles in allergy and cancer.
| ANIMAL MODELS AND IMMUNE TOLERANCE IN ALLERGY AND CANCER
The induction of allergy, often followed by re-establishment of tolerance, are important goals in allergic animal models, mostly mice. 111, 112 A range of humanized mouse models (immunocompromised mice engrafted with nonmalignant human peripheral blood lymphocytes or mononuclear cells or hematopoietic stem cells) are used for studies on allergies. 113 Comparisons among allergy mouse models are difficult as the responses vary widely. 114 Moreover, components of the human allergic response (mast cells, allergen-specific IgE and eosinophils) are unnecessary for allergy induction in certain mouse models, especially allergic asthma models. Brown Norway rats are helpful as they develop food allergy upon high-frequency intragastric dosing of allergen without adjuvant. 114 However, large amounts of antigens are needed. 111, 114 Dogs spontaneously develop allergies, but drawbacks are the high cost, limited number of strains, and greater interanimal variation compared to rodents. 111 Increasingly, allergic canine patients are introduced in comparative allergy studies. 112 Swine share dog's advantages and disadvantages plus the limitation of long dosing times required for sensitization. 111 In cancer animal models, tolerance to implanted or artificially expressed malignant cells is needed from the onset of the experiment, followed by either tumoricidal approaches or efforts to break tumour tolerance such as by immunotherapeutic approaches.
Immunocompromised mice bearing human xenograft tumours have been extensively used to study anticancer drugs, 115 but lack an adaptive immune response. This can be overcome using immunocompetent mice or rats bearing syngeneic tumours, which respond to a broad variety of immuno-stimulatory approaches such as antibodies (including IgE), antibody fusion proteins and cancer vaccines. [115] [116] [117] However, differences to the rodent immune system limit the translation of these models to humans. 115 Collectively, there are many parallels to be drawn between tolerance mechanisms at play in allergy and cancer, albeit with contrasting implications on disease progress and patient outcomes. The pursuit of further insights into these parallel mechanisms with juxtaposed clinical consequences has the potential to lead to novel therapeutic interventions to benefit both disciplines.
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